Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load

Stuart C Gordon, Zahary Krastev, Andrzej Horban, Jörg Petersen, Jan Sperl, Phillip Dinh, Eduardo B Martins, Leland J Yee, John F Flaherty, Kathryn M Kitrinos, Vinod K Rustgi, Patrick Marcellin, Stuart C Gordon, Zahary Krastev, Andrzej Horban, Jörg Petersen, Jan Sperl, Phillip Dinh, Eduardo B Martins, Leland J Yee, John F Flaherty, Kathryn M Kitrinos, Vinod K Rustgi, Patrick Marcellin

Abstract

We evaluated the antiviral response of patients with chronic hepatitis B (CHB) who had baseline high viral load (HVL), defined as having hepatitis B virus (HBV) DNA ≥ 9 log10 copies/mL, after 240 weeks of tenofovir disoproxil fumarate (TDF) treatment. A total of 641 hepatitis B e antigen (HBeAg)-negative and HBeAg-positive patients (129 with HVL) received 48 weeks of TDF 300 mg (HVL n = 82) or adefovir dipivoxil (ADV) 10 mg (HVL n = 47), followed by open-label TDF for an additional 192 weeks. Patients with confirmed HBV DNA ≥ 400 copies/mL on or after week 72 had the option of adding emtricitabine (FTC). By week 240, 98.3% of HVL and 99.2% of non-HVL patients on treatment achieved HBV DNA <400 copies/mL. Both groups had similar rates of histologic regression between baseline and week 240. Patients with HVL generally took longer to achieve HBV DNA <400 copies/mL than non-HVL patients, but by week 96, the percentages of patients with HBV DNA <400 copies/mL were similar in both groups. Among HVL patients, time to achieving HBV DNA <400 copies/mL was shorter among those initially receiving TDF, compared to ADV. No patient with baseline HVL had persistent viremia at week 240 or amino acid substitutions associated with TDF resistance.

Conclusion: CHB patients with HVL can achieve HBV DNA negativity with long-term TDF treatment, although time to HBV DNA <400 copies/mL may be longer, relative to patients with non-HVL.

Copyright © 2013 American Association for the Study of Liver Diseases.

Figures

Figure 1
Figure 1
Time to viral negativity on the basis of baseline viral load. The proportion of patients with HBV high baseline viral load (≥9 log10 copies/mL) and non-high baseline viral load (<9 log10 copies/mL) who achieved HBV DNA <400 copies/mL during TDF long-term treatment. (A) Excludes patients who received FTC. (B) Includes patients who received FTC. Vertical bars represent 95% confidence intervals.
Figure 2
Figure 2
Viral load over time. Mean HBV DNA for patients with high baseline viral load (≥9 log10 copies/mL) and non-high baseline viral load (<9 log10 copies/mL) during TDF long-term treatment. (A) Excludes patients who received FTC. (B) Includes patients who received FTC. Vertical bars represent 95% confidence intervals.
Figure 3
Figure 3
Time to viral negativity on the basis of initial therapy. The proportion of patients with HBV high baseline viral load who reached HBV DNA

References

    1. Chen C-F, Lee W-C, Yang H-I, Chang H-C, Jen C-L, Iloeje UH, et al. Changes in serum levels of HBV DNA and alanine aminotransferase determine risk for hepatocellular carcinoma. Gastroenterology. 2011;141:1240–1248. 1248.e1-2.
    1. Iloeje UH, Yang H-I, Su J, Jen C-L, You S-L, Chen C-J. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006;130:678–686.
    1. Chen C-J, Yang H-I, Su J, Jen C-L, You S-L, Lu S-N, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295:65–73.
    1. Buster EHCJ, Hansen BE, Lau GKK, Piratvisuth T, Zeuzem S, Steyerberg EW, et al. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. Gastroenterology. 2009;137:2002–2009.
    1. Cooksley G, Manns M, Lau GKK, Liaw Y-F, Marcellin P, Chow C. Effect of genotype and other baseline factors on response to peginterferon alfa-2a (40 kDa) (Pegasys) in HBeAg-positive chronic hepatitis B: results from a large, randomised study. J Hepatol. 2005;42(Suppl 2):30–31.
    1. Bonino F, Marcellin P, Lau GKK, Hadziyannis S, Jin R, Piratvisuth T, et al. Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B. Gut. 2007;56:699–705.
    1. Zoutendijk R, Reijnders JGP, Brown A, Zoulim F, Mutimer D, Deterding K, et al. Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naïve patients with a partial virological response. Hepatology. 2011;54:443–451.
    1. Yuen M-F, Seto W-K, Fung J, Wong DK-H, Yuen JC-H, Lai C-L. Three years of continuous entecavir therapy in treatment-naïve chronic hepatitis B patients: VIRAL suppression, viral resistance, and clinical safety. Am J Gastroenterol. 2011;106:1264–1271.
    1. Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med. 2008;359:2442–2455.
    1. Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, Washington MK, Germanidis G, Flaherty JF, Schall RA, Bornstein JD, Kitrinos KM, Subramanian GM, McHutchison JG, Heathcote EJ. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2012;pii S0140-6736(12)61425-1. doi: 10.1016/S0140-6736 (12)61425-1. [Epub ahead of print]
    1. Snow-Lampart A, Chappell B, Curtis M, Zhu Y, Myrick F, Schawalder J, et al. No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus. Hepatology. 2011;53:763–773.
    1. Zhu Y, Curtis M, Borroto-Esoda K. HBV DNA replication mediated by cloned patient HBV reverse transcriptase genes from HBV genotypes A-H and its use in antiviral phenotyping assays. J Virol Methods. 2011;173:340–346.
    1. Tsiang M, Rooney JF, Toole JJ, Gibbs CS. Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy. Hepatology. 1999;29:1863–1869.
    1. Yuen M-F, Lai C-L. Treatment of chronic hepatitis B: evolution over two decades. J Gastroenterol Hepatol. 2011;26(Suppl 1):138–143.
    1. Lok AS, Trinh H, Carosi G, Akarca US, Gadano A, Habersetzer F, et al. Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B. Gastroenterology. 2012;143:619–629.e1.
    1. Wu I-C, Lai C-L, Han S-HB, Han K-H, Gordon SC, Chao Y-C, et al. Efficacy of entecavir in chronic hepatitis B patients with mildly elevated alanine aminotransferase and biopsy-proven histological damage. Hepatology. 2010;51:1185–1189.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する